Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Fosså SD[au]:

Modern treatment of metastatic prostate cancer. Holm HV et al. Tidsskr Nor Laegeforen. (2017)

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Paur I et al. Clin Nutr. (2017)

Re: Behandling eller aktiv monitorering ved prostatakreft? Fosså SD et al. Tidsskr Nor Laegeforen. (2017)

Search results

Items: 1 to 50 of 876

1.

Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.

Agrawal V, Dinh PC Jr, Fung C, Monahan PO, Althouse SK, Norton K, Cary C, Einhorn L, Fossa SD, Adra N, Travis LB.

JNCI Cancer Spectr. 2019 Oct 8;4(2):pkz079. doi: 10.1093/jncics/pkz079. eCollection 2020 Apr.

2.

"Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial."

Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2020 Feb 26. pii: S0360-3016(20)30253-4. doi: 10.1016/j.ijrobp.2020.02.027. [Epub ahead of print] No abstract available.

PMID:
32112877
3.

The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.

Skalleberg J, Småstuen MC, Oldenburg J, Osnes T, Fosså SD, Bunne M.

Laryngoscope. 2020 Feb 17. doi: 10.1002/lary.28543. [Epub ahead of print]

PMID:
32065408
4.

Longitudinal kidney function outcome in aging testicular cancer survivors.

Nome RV, Cvancarova Småstuen M, Bjøro T, Kiserud CE, Fosså SD.

Acta Oncol. 2020 Apr;59(4):467-474. doi: 10.1080/0284186X.2020.1724328. Epub 2020 Feb 11.

PMID:
32043400
5.

A cross-sectional study of current work ability after radical prostatectomy.

Dahl AA, Brennhovd B, Fosså SD, Axcrona K.

BMC Urol. 2020 Jan 31;20(1):9. doi: 10.1186/s12894-020-0579-9.

6.

Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study.

Kvammen Ø, Myklebust TÅ, Solberg A, Møller B, Klepp OH, Fosså SD, Tandstad T.

PLoS One. 2019 Dec 18;14(12):e0225942. doi: 10.1371/journal.pone.0225942. eCollection 2019.

7.

Testicular Cancer Survivorship.

Fung C, Dinh PC, Fossa SD, Travis LB.

J Natl Compr Canc Netw. 2019 Dec;17(12):1557-1568. doi: 10.6004/jnccn.2019.7369. Review.

PMID:
31805527
8.

Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique.

Fosså SD, Beyer B, Dahl AA, Aas K, Eri LM, Kvan E, Falk RS, Graefen M, Huland H, Berge V.

Scand J Urol. 2019 Dec;53(6):385-391. doi: 10.1080/21681805.2019.1693625. Epub 2019 Dec 4.

PMID:
31797716
9.

Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome.

Bucher-Johannessen C, Page CM, Haugen TB, Wojewodzic MW, Fosså SD, Grotmol T, Haugnes HS, Rounge TB.

Clin Epigenetics. 2019 Dec 3;11(1):179. doi: 10.1186/s13148-019-0764-4.

10.

Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial.

Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):706-714. doi: 10.1016/j.ijrobp.2019.11.027. Epub 2019 Nov 28.

PMID:
31786279
11.

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.

Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS.

Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32704. [Epub ahead of print]

PMID:
31597192
12.

Extent of disease at first cancer presentation and previous anxiety and depressive symptoms: the HUNT study.

Stewart R, Fosså SD, Hotopf M, Mykletun A.

Br J Psychiatry. 2019 Oct 7:1-7. doi: 10.1192/bjp.2019.211. [Epub ahead of print]

PMID:
31587671
13.

Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients.

Kvåle R, Myklebust TÅ, Fosså SD, Aas K, Ekanger C, Helle SI, Honoré A, Møller B.

Prostate. 2019 Dec;79(16):1852-1860. doi: 10.1002/pros.23911. Epub 2019 Sep 30.

PMID:
31566779
14.

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.

Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC Jr, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME.

Clin Cancer Res. 2019 Oct 1;25(19):5913-5924. doi: 10.1158/1078-0432.CCR-19-0113. Epub 2019 Jul 11.

PMID:
31296530
15.

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2019 May 1;17(5):459-468. doi: 10.6004/jnccn.2018.7109.

PMID:
31085753
16.

Limited evidence of non-response bias despite modest response rate in a nationwide survey of long-term cancer survivors-results from the NOR-CAYACS study.

Lie HC, Rueegg CS, Fosså SD, Loge JH, Ruud E, Kiserud CE.

J Cancer Surviv. 2019 Jun;13(3):353-363. doi: 10.1007/s11764-019-00757-x. Epub 2019 Apr 16.

PMID:
30993649
17.

Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.

El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC Jr, Frisina RD, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Gamazon ER, Cox NJ, Huddart R, Ardeshir-Rouhani-Fard S, Monahan P, Fossa SD, Einhorn LH, Travis LB, Dolan ME.

Clin Cancer Res. 2019 Jul 1;25(13):4104-4116. doi: 10.1158/1078-0432.CCR-18-3179. Epub 2019 Apr 5.

PMID:
30952644
18.

Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors.

Dahl AA, Fosså SD, Lie HC, Loge JH, Reinertsen KV, Ruud E, Kiserud CE.

J Adolesc Young Adult Oncol. 2019 Jun;8(3):304-311. doi: 10.1089/jayao.2018.0109. Epub 2019 Mar 22.

PMID:
30900929
19.

Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors.

Gjerset GM, Kiserud CE, Loge JH, Fosså SD, Wisløff T, Gudbergsson SB, Oldervoll LM, Thorsen L.

Acta Oncol. 2019 May;58(5):682-689. doi: 10.1080/0284186X.2018.1562210. Epub 2019 Mar 12.

PMID:
30862228
20.

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood.

Bøhn SH, Thorsen L, Kiserud CE, Fosså SD, Lie HC, Loge JH, Wisløff T, Haugnes HS, Reinertsen KV.

Acta Oncol. 2019 May;58(5):753-762. doi: 10.1080/0284186X.2018.1557344. Epub 2019 Jan 30.

PMID:
30696351
21.

Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V.

World J Urol. 2019 Aug;37(8):1571-1580. doi: 10.1007/s00345-018-2570-6. Epub 2018 Nov 27.

PMID:
30483947
22.

Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.

Radiother Oncol. 2019 Mar;132:211-217. doi: 10.1016/j.radonc.2018.10.013. Epub 2018 Oct 30.

PMID:
30389241
23.

Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.

Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD.

Acta Obstet Gynecol Scand. 2019 Feb;98(2):240-249. doi: 10.1111/aogs.13477. Epub 2018 Nov 22.

PMID:
30289161
24.

Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol.

van der Kooi ALF, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, van den Berg M, Berger C, Calaminus G, Dirksen U, Winther JF, Fosså SD, Grabow D, Haupt R, Kaiser M, Kepak T, Kremer L, Kruseova J, Modan-Moses D, Ranft A, Spix C, Kaatsch P, Laven JSE, van Dulmen-den Broeder E, Uitterlinden AG, van den Heuvel-Eibrink MM; PanCareLIFE Consortium.

BMC Cancer. 2018 Sep 26;18(1):930. doi: 10.1186/s12885-018-4834-3.

25.

Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE).

van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P, van Dulmen-den Broeder E; PanCareLIFE Consortium.

JMIR Res Protoc. 2018 Sep 14;7(9):e10824. doi: 10.2196/10824.

26.

Physical activity and associations with treatment-induced adverse effects among prostate cancer patients.

Bøhn SH, Fosså SD, Wisløff T, Thorsen L.

Support Care Cancer. 2019 Mar;27(3):1001-1011. doi: 10.1007/s00520-018-4389-5. Epub 2018 Aug 9.

PMID:
30094728
27.

Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS.

Acta Oncol. 2018 Oct;57(10):1392-1400. doi: 10.1080/0284186X.2018.1473641. Epub 2018 May 18.

PMID:
29775128
28.

Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.

Fung C, Dinh P Jr, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB.

Adv Urol. 2018 Feb 18;2018:8671832. doi: 10.1155/2018/8671832. eCollection 2018. Review.

29.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group.

J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.

30.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD; Platinum Study Group.

Clin Genitourin Cancer. 2018 Aug;16(4):e761-e769. doi: 10.1016/j.clgc.2018.01.011. Epub 2018 Feb 5.

31.

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC, Sesso HD, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2018 Mar;16(3):257-265. doi: 10.6004/jnccn.2017.7046.

32.

Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.

Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD.

Acta Oncol. 2018 Aug;57(8):1075-1083. doi: 10.1080/0284186X.2018.1433323. Epub 2018 Jan 31.

PMID:
29384420
33.

Lowered reference limits for hCG improve follow-up of patients with hCG-producing tumors.

Nome RV, Bjøro T, Paus E, Bjerner J, Fosså SD, Steen R, Nustad K, Bolstad N.

Clin Biochem. 2018 Feb;52:73-79. doi: 10.1016/j.clinbiochem.2017.11.016. Epub 2017 Dec 2.

34.

Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.

Axcrona K, Nilsson R, Brennhovd B, Sørebø Ø, Fosså SD, Dahl AA.

BMC Urol. 2017 Dec 2;17(1):111. doi: 10.1186/s12894-017-0302-7.

35.

Genetic factors influencing prostate cancer risk in Norwegian men.

Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, Djurovic S, Andreassen OA, Axcrona K, Mills IG, Xu J, Maehle L, Fosså SD, Isaacs WB.

Prostate. 2018 Feb;78(3):186-192. doi: 10.1002/pros.23453. Epub 2017 Nov 27.

PMID:
29181843
36.

Correction to: Norwegian reference values for the Short-Form Health Survey 36: development over time.

Jacobsen EL, Bye A, Aass N, Fosså SD, Grotmol KS, Kaasa S, Loge JH, Moum T, Hjermstad MJ.

Qual Life Res. 2018 May;27(5):1213-1215. doi: 10.1007/s11136-017-1708-0.

37.

Cancer Survivorship in Adults.

Kiserud CE, Dahl AA, Fosså SD.

Recent Results Cancer Res. 2018;210:123-143. doi: 10.1007/978-3-319-64310-6_8.

PMID:
28924683
38.

Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors.

Johannsdottir IMR, Hamre H, Fosså SD, Loge JH, Drolsum L, Lund MB, Nordsletten L, Kiserud C.

J Adolesc Young Adult Oncol. 2017 Sep;6(3):470-476. doi: 10.1089/jayao.2017.0018. Epub 2017 Aug 24.

PMID:
28837384
39.

H.V. Holm og medarbeidere svarer.

Holm HV, Dahl AA, Klepp OH, Fosså SD.

Tidsskr Nor Laegeforen. 2017 Aug 21;137(14-15). doi: 10.4045/tidsskr.17.0579. Print 2017 Aug 22. Norwegian. No abstract available.

PMID:
28828789
Free Article
40.

Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway.

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD.

Urology. 2017 Dec;110:140-147. doi: 10.1016/j.urology.2017.07.048. Epub 2017 Aug 18.

PMID:
28823634
41.

Norwegian reference values for the Short-Form Health Survey 36: development over time.

Jacobsen EL, Bye A, Aass N, Fosså SD, Grotmol KS, Kaasa S, Loge JH, Moum T, Hjermstad MJ.

Qual Life Res. 2018 May;27(5):1201-1212. doi: 10.1007/s11136-017-1684-4. Epub 2017 Aug 14. Erratum in: Qual Life Res. 2017 Nov 21;:.

42.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11.

43.

A controlled study of the influence of comorbidity on activities of daily living in elderly cancer survivors (the HUNT-3 survey).

Grov EK, Fosså SD, Dahl AA.

J Geriatr Oncol. 2017 Sep;8(5):328-335. doi: 10.1016/j.jgo.2017.05.007. Epub 2017 Jun 16.

PMID:
28629695
44.

Feasibility of a physical activity intervention during and shortly after chemotherapy for testicular cancer.

Thorsen L, Kirkegaard C, Loge JH, Kiserud CE, Johansen ML, Gjerset GM, Edvardsen E, Hamre H, Ikdahl T, Fosså SD.

BMC Res Notes. 2017 Jun 15;10(1):214. doi: 10.1186/s13104-017-2531-y.

45.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

46.

Modern treatment of metastatic prostate cancer.

Holm HV, Dahl AA, Klepp OH, Fosså SD.

Tidsskr Nor Laegeforen. 2017 Jun 6;137(11):803-805. doi: 10.4045/tidsskr.16.0265. eCollection 2017 Jun. Review. English, Norwegian.

47.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.

van Leeuwen M, Kieffer JM, Efficace F, Fosså SD, Bolla M, Collette L, Colombel M, De Giorgi U, Holzner B, van de Poll-Franse LV, van Poppel H, White J, de Wit R, Osanto S, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group; Genito-Urinary Cancers Group and Radiation Oncology Group; and the NCRN Testis Clinical Studies Group.

Health Qual Life Outcomes. 2017 May 11;15(1):97. doi: 10.1186/s12955-017-0670-4.

48.

Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study.

Vatne K, Stensvold A, Myklebust TÅ, Møller B, Svindland A, Kvåle R, Fosså SD.

Acta Oncol. 2017 Oct;56(10):1295-1301. doi: 10.1080/0284186X.2017.1314006. Epub 2017 Apr 19.

PMID:
28422584
49.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.

50.

Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma.

Lie HC, Mellblom AV, Brekke M, Finset A, Fosså SD, Kiserud CE, Ruud E, Loge JH.

Support Care Cancer. 2017 Aug;25(8):2445-2454. doi: 10.1007/s00520-017-3651-6. Epub 2017 Feb 24.

PMID:
28236146

Supplemental Content

Loading ...
Support Center